LENZ Therapeutics heads into its third-quarter report with a simple but unforgiving question hanging over it: did the July spike in VIZZ prescriptions keep going? Last quarter, management pointed to script growth of more than 45% from June to July after launching telehealth prescribing and a national TV campaign. In the same breath, it warned that one month does not make a trend. This report covers the first full quarter of that consumer push. For a stock that has nearly halved since the last update, it is the clearest chance yet to show whether the presbyopia drop can grow without leaning on eye care professionals to drive demand.
The headline numbers will look ugly, but mostly for mechanical reasons. Consensus calls for a loss of $0.99 per share on revenue of about $4.0 million. That would be a 68% drop in revenue from a year ago, and the loss would widen from $0.59. The year-ago quarter was flattered by a $12.5 million licensing payment, so the comparison says little about the underlying business. The prior quarter is a better yardstick. Revenue was $5.5 million then, and $3.8 million of that came from ex-US milestones tied to Canada and Greater China. Product revenue was only $1.7 million, flat from the quarter before even though pack volume rose 9%. Management has not offered formal guidance. The figure that matters most is therefore product revenue, and whether it finally breaks meaningfully above that $1.7 million plateau.
The last call left a mixed but modestly constructive picture, and this report should test both halves of it. The encouraging half rests on persistence and reach. Early e-pharmacy cohorts were tracking toward roughly five packs a year. More than 60% of those patients had bought more than one pack. The prescriber base had climbed past 13,000. If those cohorts are holding up and telehealth is adding new patients on top of them, quarterly volume should rise well beyond the 27,000 packs sold in the second quarter. The less comfortable half is that management conceded something important. Near-universal awareness among eye doctors has not turned into steady repeat prescribing, and retail pharmacy uptake has been weak. As a result, growth now depends on consumers asking for the product. Evidence that the TV and telehealth spending is producing sustained new starts would back that strategy. A fade after July would undercut it.
Cost discipline is the other key thread. Adjusted SG&A fell 14% in the second quarter to $34.9 million. Management also signaled it wanted to see third-quarter data before committing more capital, a notably cooler tone than the expansionary talk of late 2025. Cash fell to $220 million from $292 million two quarters earlier. Investors will want spending to stay contained even with a national ad campaign running. They will also want to hear whether management plans to scale up the consumer push or pare it back. Updates on the nine ex-US regulatory submissions and any year-end approvals could add milestone revenue, but those payments are lumpy and do not prove the US launch is working.
The market has rendered a harsh preliminary verdict. Shares are down about 46% since the last report while the S&P 500 was essentially flat. At $3.22, the stock sits barely above its post-earnings low of $3.12 and far below its 200-day moving average of $8.52. Sentiment has also soured, moving to 12.7% bearish from 4.7% bearish heading into the prior report. That pessimism sets a low bar. Even so, a low bar does not guarantee a relief rally if the volume data disappoints.
Ultimately, this quarter comes down to whether consumer-driven demand can replace the stalled physician channel as LENZ's growth engine. Rising pack volume, durable refill behavior and product revenue moving clearly higher would keep the launch story intact. Another flat quarter would leave investors questioning whether VIZZ can reach scale before the cash runs thinner.